首页 | 本学科首页   官方微博 | 高级检索  
     

镇脑宁胶囊联合氯沙坦钾治疗原发性高血压的临床研究
引用本文:薛延辉,李春霞,尚敬. 镇脑宁胶囊联合氯沙坦钾治疗原发性高血压的临床研究[J]. 现代药物与临床, 2021, 36(7): 1467-1470
作者姓名:薛延辉  李春霞  尚敬
作者单位:平顶山市新华区人民医院 内分泌科,河南 平顶山 467000;河南省人民医院 内分泌科,河南 郑州 450000
摘    要:目的 探讨镇脑宁胶囊联合氯沙坦钾片治疗原发性高血压的临床效果.方法 选取2017年8月—2020年8月于平顶山市新华区人民医院诊疗的106例原发性高血压患者,根据入院顺序分成对照组和治疗组,每组分别53例.对照组口服氯沙坦钾片,50 mg/次,1次/d;治疗组患者在对照组基础上口服镇脑宁胶囊,1.2 g/次,3次/d....

关 键 词:镇脑宁胶囊  氯沙坦钾片  原发性高血压  尿微量白蛋白  N-端脑利钠肽前体  血管性血友病因子
收稿时间:2021-01-07

Clinical study on Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension
XUE Yan-hui,LI Chun-xi,SHANG Jing. Clinical study on Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension[J]. Drugs & Clinic, 2021, 36(7): 1467-1470
Authors:XUE Yan-hui  LI Chun-xi  SHANG Jing
Affiliation:Department of Endocrine, Pingdingshan Xinhua District People''s Hospital, Pingdingshan 467000, China; Department of Endocrine, Henan Provincial People''s Hospital, Zhengzhou 450000, China
Abstract:Objective To explore the clinical effect of Zhennaoning Capsules combined with losartan potassium in treatment of essential hypertension. Methods Patients (106 cases) with essential hypertension in Pingdingshan Xinhua District People''s Hospital from August 2017 to August 2020 were divided into control and treatment groups according to the order of admission, and each group had 53 cases. Patients in the control group were po administered with Losartan Potassium Tablets, 50 mg/time, once daily. Patients in the treatment group were po administered with Zhennaoning Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the 24 h mean systolic blood pressure and mean diastolic blood pressure, the serum NT-proBNP, vWF and urinary microalbumin levels in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate of the treatment group was 96.23%, which was significantly higher than 84.91% of the control group (P < 0.05). After treatment, 24 h average systolic blood pressure and 24 h average diastolic blood pressure were significantly decreased in two groups (P < 0.05), and which in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the levels of serum NT-proBNP, vWF and urinary microalbumin in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Zhennaoning Capsules combined with losartan potassium has significant curative effect in treatment of essential hypertension, can effectively control the level of ambulatory blood pressure and reduce the level of serological indexes with high safety, which has a certain clinical application value.
Keywords:Zhennaoning Capsules  Losartan Potassium Tablets  essential hypertension  urinary microalbumin  NT-proBNP  vWF
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号